Dow Jones
29.590,41 -486,29 (-1,62%) Nasdaq
10.867,93 -198,87 (-1,80%) Nikkei 225
26.462,57 -691,26 (-2,55%) EUR/USD
0,9638 -0,0050 (-0,52%) BTC-EUR
19.480,89 -373,75 (-1,88%) CMC Crypto 200
430,44 -14,09 (-3,17%)
Illumina, Inc. (ILMN)
Dopo ore:
| Chiusura precedente | 193,49 |
| Aperto | 193,04 |
| Denaro | 0,00 x 1000 |
| Lettera | 0,00 x 1000 |
| Min-Max giorno | 188,42 - 194,46 |
| Intervallo di 52 settimane | 173,45 - 431,11 |
| Volume | |
| Media Volume | 1.443.479 |
| Capitalizzazione | 29,947B |
| Beta (5 anni mensile) | 1,16 |
| Rapporto PE (ttm) | 42,88 |
| EPS (ttm) | 4,44 |
| Prossima data utili | 02 nov 2022 - 07 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 243,18 |
- GlobeNewswire
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti Bioscien
- GlobeNewswire
Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices
The collaboration will explore the uptake and actionability of comprehensive genomic profiling in patients with advanced cancersSAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced a partnership with Illumina, Inc. (NASDAQ:ILMN), aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community onc
- GlobeNewswire
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity (“PIPE”) financing and from non-redemption agreements - - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morga
